… These properties have made chitosan an attractive non-viral vector for gene therapy. In …
gene therapy, where enhanced particle uptake was evidenced by human blood-brain barrier …

… viral vector systems for gene therapy are promising treatment … to risk assessment and
developing procedures to minimize … the viral vector systems utilized for gene therapy and some of …

… and spleen were major barriers of Advs in human gene therapy. … , AAV vectors provide a
safer and well-tolerated gene therapy … pathogenicity and immunogenicity in humans. [ 140-145 ] …

… viral vector-based gene therapy landscape, we focus on these three highly regarded vector
… cellular toxicity continue to be major obstacles for Ad gene therapy, despite the fact that Ad …

… drugs approved worldwide from 1998 to 2019 in details, including names, indications,
dates of approval, companies, vectors, the applied technologies and mechanisms of gene …

… : This method has been developed to circumvent the intracellular hindrance of endosomes
as well as … 3 shows the viral and nonviral vectors used for cancer cell-targeted gene therapy. …

… Therefore, these vectors have been widely applied in gene therapy protocols of several
retinal … These challenges continue to pose obstacles for gene therapy researches and are …

… The ability of viruses to protect transgenes from biological degradation and their capability
to efficiently cross cellular barriers have allowed gene therapy research to develop new …

… Delivery of genetically engineered gene therapy vector using adeno-associated virus …
that encompasses the tight junctions of the blood–brain barrier (BBB) [Citation28] ( Figure 2 ). …

… an overview of gene therapy types and delivery methods, gene editing … obstacle that
may generate undesirable complications and limit efficacy [6]. Vectors used for gene therapy …